PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against Hard-to-Treat cancers
Disease control TerminatedThis early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…
Matched conditions: PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 05:48 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…
Matched conditions: PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC